SpeculatingStocks.com: Stock Picks, Stock Analysis and Stock Updates Daily
Enter your Email Address for Stock Alerts Intraday Stock Updates
SpeculatingStocks.com Homepage Stock Market Services Offered Our Winning Stock Pick Success

Stock Picks


Stock Notes
Stock Updates on Past Stock Picks
Speculation Board
Testimonials from Viewers
The SpeculatingStocks.com Team
Links and Affiliates
Contact us and More Info
Purchase a Stock Picks Package
SpeculatingStocks.com Press and Media Page for Stock Market / Stock Information


Join our Stock Newsletter
Enter your Email Address


SpeculatingStocks.com RSS Feed


Social Bookmark SpeculatingStocks.com

SpeculatingStocks.com RSS Feed


Receive our Feed via Email:

Delivered by FeedBurner







 

November 24, 2008

SpeculatingStocks.com Stock Pick: Rite Aid Corporation (RAD)

Stock Price: $0.31

Rite Aid Corporation is a drugstore chain with more than 4,900 stores in 31 states and the District of Columbia. The company's fiscal 2008 annual sales totaled more than $24.3 billion.

Rite Aid is a major brand that continues to expand. Patients fill their prescriptions at Rite Aid for various ailments and shop for over-the-counter medication for cold and flu and other illnesses.

RAD has been down significantly this year, but we see the potential for a major turn around in the future for RAD. Three independent proxy advisory firms have recommended RAD stockholders support RAD's Board of Directors' plan for a reverse split. The reverse stock split could be approved on December 2nd.

Reverse stock split is never a good phrase to investors, but in this case it looks like it must be done and we believe most of the negativity is already priced into RAD. After the reverse split, we expect investors to look at RAD in a new, refreshing light.

We believe RAD will receive major attention as a cold and flu season play over the next 1 - 2 months. Also, we expect RAD to begin its turn around.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Please Read our Legal Disclaimer Our Privacy Policy